Toll Free: 1-888-928-9744

Kaposi Sarcoma - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 83 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kaposi Sarcoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Kaposi Sarcoma - Pipeline Review, H1 2016', provides an overview of the Kaposi Sarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma
- The report reviews pipeline therapeutics for Kaposi Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Kaposi Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Kaposi Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Kaposi Sarcoma


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kaposi Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kaposi Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Kaposi Sarcoma Overview 7 Therapeutics Development 8 Pipeline Products for Kaposi Sarcoma - Overview 8 Pipeline Products for Kaposi Sarcoma - Comparative Analysis 9 Kaposi Sarcoma - Therapeutics under Development by Companies 10 Kaposi Sarcoma - Therapeutics under Investigation by Universities/Institutes 11 Kaposi Sarcoma - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Kaposi Sarcoma - Products under Development by Companies 15 Kaposi Sarcoma - Products under Investigation by Universities/Institutes 16 Kaposi Sarcoma - Companies Involved in Therapeutics Development 17 Aphios Corporation 17 AstraZeneca Plc 18 Biogenomics Limited 19 CytRx Corporation 20 Delenex Therapeutics AG 21 Tumorend, LLC 22 Vironika, LLC 23 Kaposi Sarcoma - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 aldoxorubicin hydrochloride - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 brolucizumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CM-101 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CSTATI-1 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 doxorubicin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 interferon alfa-2a - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 interferon alfa-2b - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 paclitaxel - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 selumetinib sulfate - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecule for Kaposi's Sarcoma - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 vif-1 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Kaposi Sarcoma - Recent Pipeline Updates 53 Kaposi Sarcoma - Dormant Projects 70 Kaposi Sarcoma - Discontinued Products 72 Kaposi Sarcoma - Product Development Milestones 73 Featured News & Press Releases 73 May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update 73 Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 73 Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi's Sarcoma 74 Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages 75 Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 76 May 28, 2015: Delenex Presents Anti-Tumor Activity of DLX1008 78 Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients 78 Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma 79 Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma 80 Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 80 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables
Number of Products under Development for Kaposi Sarcoma, H1 2016 8 Number of Products under Development for Kaposi Sarcoma - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Kaposi Sarcoma - Pipeline by Aphios Corporation, H1 2016 17 Kaposi Sarcoma - Pipeline by AstraZeneca Plc, H1 2016 18 Kaposi Sarcoma - Pipeline by Biogenomics Limited, H1 2016 19 Kaposi Sarcoma - Pipeline by CytRx Corporation, H1 2016 20 Kaposi Sarcoma - Pipeline by Delenex Therapeutics AG, H1 2016 21 Kaposi Sarcoma - Pipeline by Tumorend, LLC, H1 2016 22 Kaposi Sarcoma - Pipeline by Vironika, LLC, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Kaposi Sarcoma Therapeutics - Recent Pipeline Updates, H1 2016 53 Kaposi Sarcoma - Dormant Projects, H1 2016 70 Kaposi Sarcoma - Dormant Projects (Contd..1), H1 2016 71 Kaposi Sarcoma - Discontinued Products, H1 2016 72


List of Figures
Number of Products under Development for Kaposi Sarcoma, H1 2016 8 Number of Products under Development for Kaposi Sarcoma - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Top 10 Targets, H1 2016 25 Number of Products by Stage and Top 10 Targets, H1 2016 25 Number of Products by Top 10 Mechanism of Actions, H1 2016 27 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27 Number of Products by Routes of Administration, H1 2016 29 Number of Products by Stage and Routes of Administration, H1 2016 29 Number of Products by Molecule Types, H1 2016 31 Number of Products by Stage and Molecule Types, H1 2016 31

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify